四川科伦药业股份有限公司 2024 年度第一期资产担保债务融资工具（科创票据）发行结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：002422 证券简称：科伦药业 公告编号：2024-084 本期资产担保债务融资工具（科创票据）募集资金用途为补充流动资金。 特此公告。 四川科伦药业股份有限公司董事会 2024年7月4日 四川科伦药业股份有限公司（以下简称"公司"）《关于公司发行非金融 企业债务融资工具的议案》已于2023年4月12日经公司第七届董事会第二十六次 会议审议通过，并经2023年5月4日召开的公司2022年年度股东大会审议批准。 相关董事会和股东大会决议公告详见2023年4月14日和2023年5月5日的《证券时 报》《上海证券报》《证券日报》和《中国证券报》以及公司指定信息披露网 站巨潮资讯网（www.cninfo.com.cn）。 公司于2023年12月25日收到中国银行间市场交易商协会（以下简称"交易 商协会"）下发的《接受注册通知书》（以下简称《通知书》）（中市协注 [2023]SCP529号），交易商协会同意接受公司超短期 ...

证券代码：002422 证券简称：科伦药业 公告编号：2024-083 四川科伦药业股份有限公司 关于子公司创新药物注射用 SKB518 新药临床试验申请获国家药品 监督管理局批准的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）近日获悉，公 司控股子公司四川科伦博泰生物医药股份有限公司（以下简称"科伦博泰"）已于 2024 年 6 月 17 日收到国家药品监督管理局(NMPA)药品审评中心批准其开发的 创新药物注射用 SKB518 新药临床试验申请的临床试验通知书。 注射用 SKB518 是一款由科伦博泰针对靶点生物学特点，利用"OptiDCTM"平 台技术研发的具有自主知识产权的创新抗体偶联药物，在临床前展现了良好的有 效性和安全窗，拟用于治疗晚期实体瘤。 科伦博泰将按照国家药品监督管理局签发的临床试验通知书的要求，组织实 施注射用 SKB518 的临床试验。 二、风险提示 创新药物研发过程周期长、环节多、能否开发成功及商业化具有一定的不确 定性，敬请广大投资者谨慎决策，注意防范投资风险。公司 ...

证券代码：002422 证券简称：科伦药业 公告编号：2024-082 四川科伦药业股份有限公司 关于公司控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 二、股东股份质押的基本情况 | | 是否为控 | | | 占公 | 是否为限 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东姓 | 股股东或 | 本次质押 | 占其所 | 司总 | 售股（如 | 为补 | | | | 质押用 | | | 第一大股 | | 持股份 | | 是，注明 | | 质押起始日 | 质押到期日 | 质权人 | | | 名 | | （股） | | 股本 | | 充质 | | | | 途 | | | 东及其一 | | 比例 | 比例 | 限售类 | 押 | | | | | | | 致行动人 | | | | 型） | | | | | | | | | | | | | | | | 华泰证券 （上海）资 | 其他： | | 刘革新 | ...

Summary of the Conference Call for Kelun Pharmaceutical Company Overview - **Company**: Kelun Pharmaceutical - **Date of Call**: June 6, 2024 - **Key Focus**: Discussion on the company's performance, product lines, and market outlook Key Points Industry and Market Dynamics - The pharmaceutical industry, particularly in the infusion and antibiotic segments, has shown strong demand due to various infections and seasonal factors, leading to an unexpected increase in sales in Q1 2024 [4][5] - The overall market for infusions is expected to stabilize after a slight decline in Q2, aligning with seasonal trends and infection rates [4][5] - The competitive landscape remains stable with no significant new production capacity entering the market, which helps maintain price stability [8][25] Business Segments Performance - **Infusion Segment**: - Q1 performance exceeded expectations due to high demand for infusions and antibiotics [4] - Long-term growth is anticipated from three main factors: optimization of product structure, increased volume of key products, and enhanced distribution efficiency through centralized procurement [6][7] - The infusion segment is projected to maintain steady growth despite a slight decline in Q2 [6][7] - **Antibiotics**: - The demand for antibiotics is stable, with a slight price increase of around 5% compared to the previous year [10] - The company expects to adjust its annual forecasts based on Q2 performance [10] - **Generic Drugs**: - The performance of generics has improved, with a recovery in sales volume and new product launches contributing positively [12] - The company is restructuring its team to enhance the management of its generic product lines [11][12] Innovation and R&D - **Innovative Drugs**: - The company is advancing its clinical trials, with multiple products expected to receive approval by the end of 2024 or early 2025 [14][15] - A dedicated commercialization team is being established, with plans to expand to 300-400 members by the end of 2024 and 500-600 by 2025 [31][32] - **Synthetic Biology**: - The company is focusing on synthetic biology with several products in the pipeline, including melatonin and PHA, expected to generate significant revenue in the coming years [47][49] Financial Outlook - The company anticipates a stable increase in profits, with a focus on maintaining a balance between R&D investments and operational costs [66] - Sales expense ratios are expected to decrease due to improved compliance and operational efficiency [34] Strategic Initiatives - The company is committed to enhancing its market position through product innovation and strategic partnerships, particularly in the areas of nutrition and therapeutic infusions [54][56] - There is a strong emphasis on domestic market penetration and potential for replacing foreign brands in the nutrition infusion segment [54] Conclusion - Overall, Kelun Pharmaceutical is positioned for steady growth across its various segments, with a strong focus on innovation, market stability, and operational efficiency. The company is optimistic about its future performance and market opportunities, particularly in the infusion and innovative drug sectors [66]

Company and Industry Summary Company Involved - The document discusses a company named 克伦 (Krun), which has been in operation for a long time and has shown significant progress over the years [1]. Core Points and Arguments - The company has consistently surpassed its previous achievements, indicating a strong growth trajectory [1]. - Notable changes have been observed in the company over the past two years, suggesting a dynamic shift in its operations or market position [1]. Other Important but Possibly Overlooked Content - The reference to the end of 2022 implies that the company may have undergone substantial developments or strategic changes during that period, which could be relevant for understanding its current standing [1].

证券代码：002422 证券简称：科伦药业 公告编号：2024-081 四川科伦药业股份有限公司 关于 2021 年限制性股票激励计划首次授予部分第二个解除限售期 解除限售股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 特别提示： 1、四川科伦药业股份有限公司（以下简称"公司"）2021年限制性股票激励 计划（以下简称"本激励计划"）首次授予部分的限制性股票第二个解除限售期 解除限售条件已成就，符合解除限售条件的激励对象人数为347人，可解除限售 的限制性股票数量为215.4267万股，约占公司目前总股本的0.1345%。 2、本次解除限售股份上市流通日为2024年6月6日。 公司于2024年5月20日召开了第八届董事会第一次会议和第八届监事会第一 次会议，会议审议通过了《关于2021年限制性股票激励计划第二个解除限售期解 除限售条件成就的议案》，董事会认为公司本激励计划第二个解除限售期解除限 售条件已成就，监事会发表了同意的意见。根据公司2021年度股东大会对董事会 的授权及《四川科伦药业股份有限公司2021年限制性股票激励计划》（ ...

证券代码：002422 证券简称：科伦药业 公告编号：2024-080 四川科伦药业股份有限公司 关于2021年员工持股计划第二个锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）2021年员工持股计划 （以下简称"本员工持股计划"）第二个锁定期于2024年5月26日届满，根据 2023年度公司层面业绩和个人层面绩效考核结果，本员工持股计划第二个解锁 期解锁条件已达成。根据《关于上市公司实施员工持股计划试点的指导意见》 及《深圳证券交易所上市公司自律监管指引第1号——主板上市公司规范运作》 等相关规定，现将本员工持股计划第二个锁定期届满及解锁情况公告如下： 一、本员工持股计划的基本情况 公司于2021年11月29日、2021年12月7日、2022年5月5日分别召开第七届董 事会第六次会议、第七届董事会第七次会议、2021年年度股东大会，审议通过 公司2021年员工持股计划。 本次员工持股计划持有人范围为公司（含控股子公司）的高级管理人员、 监事及核心员工，总人数共9人，股份来源包含公司回购专用证 ...

证券代码：002422 证券简称：科伦药业 公告编号：2024-079 四川科伦药业股份有限公司 关于公司控股股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"或"科伦药业"）于近日收 到公司控股股东刘革新先生关于其持有的公司部分股份质押及解除质押的通知， 相关情况具体如下： | 一、股东股份解除质押的基本情况 | | --- | | 股东姓 | 是否为控股股 东或第一大股 | 本次解除质 押股份数量 | 占其所持股 | 占公司总股 | 起始日 | 解除日 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名 | 东及其一致行 | （股） | 份比例 | 本比例 | | | | | | 动人 | | | | | | | | 刘革新 | 是 | 8,900,000 | 2.35% | 0.56% | 2023/5/24 | 2024/5/23 | 华泰证券（上海） | | | | | | | | | 资产管理有限公司 | ...

Investment Rating - The report assigns a "Buy" rating for the company with a target price of 39.48 CNY based on a 21x P/E ratio for 2024 [1][4]. Core Views - The company is experiencing a robust transformation driven by three key factors, leading to a solid revenue growth of 12.7% in 2023, reaching 21.45 billion CNY, and a significant net profit increase of 44.0%, totaling 2.46 billion CNY [1][18]. - The ADC platform is positioned as a domestic leader, with two ADC products, SKB264 and A166, expected to enter the commercialization phase soon, indicating a promising future for the company's innovative drug pipeline [1][34]. - The company has established a comprehensive synthetic biology production system, benefiting from the recovery of market demand and the expansion of generic drug sales through centralized procurement [1][3]. Summary by Sections Company Overview - The company has evolved from a focus on infusion products to a diversified portfolio including antibiotics, generics, and innovative drugs, establishing a "product" structure with subsidiaries Kolun Pharmaceutical, Kolun Biotechnology, and Chuaning Biology [1][13]. Innovative Drug Segment - Kolun Biotechnology is recognized as a domestic leader in the ADC field, with multiple ADC products nearing commercialization, including SKB264, the first domestic TROP-2 ADC, and A166, the first HER2 ADC for breast cancer in China [1][30][34]. - The ADC platform has received significant validation from Merck, which holds approximately 20.99% of Kolun Biotechnology's shares, enhancing the company's commercial prospects [1][33]. Non-Infusion Segment - The company leads in antibiotic intermediates, with a strong focus on synthetic biology and generics, which are expected to contribute significantly to revenue growth [1][3]. - The non-infusion business has seen a compound annual growth rate (CAGR) of 7.7% from 2018 to 2023, driven by the recovery of antibiotic prices and the approval of new products [1][21]. Infusion Segment - The company maintains a strong position in the domestic infusion market, with innovative products like the "Keli Bag" enhancing cash flow and market share [1][7]. - The infusion segment's gross margin remains high at 64.0% in 2023, supported by an optimized product structure [1][23]. Financial Projections - The company forecasts earnings per share (EPS) of 1.88 CNY, 2.11 CNY, and 2.36 CNY for 2024, 2025, and 2026, respectively, indicating a positive growth trajectory [1][3].

Investment Rating - The report gives a "Buy" rating for the company with a target price of 39.48 CNY based on a 21x P/E ratio for 2024 [1]. Core Views - The company is experiencing a three-pronged growth strategy, with innovation on track and a robust operational structure formed by Kelun Pharmaceutical, Kelun Biotech, and Chuan Ning Biological [1][13]. - The ADC platform is leading domestically, with two ADC products expected to enter commercialization soon, including SKB264 and A166, which have significant market potential [1][35]. - The company has a strong pipeline in non-ADC products, with several expected approvals in the oncology and non-oncology fields [1][6]. Summary by Sections Financial Performance - In 2023, the company achieved a revenue of 21.45 billion CNY (+12.7%) and a net profit of 2.46 billion CNY (+44.0%), indicating strong performance and improved profitability [1][18]. - The company forecasts earnings per share of 1.88 CNY, 2.11 CNY, and 2.36 CNY for 2024, 2025, and 2026 respectively [1][3]. Innovation and R&D - The company has invested over 12.2 billion CNY in R&D from 2013 to 2023, with a CAGR of 17.2%, indicating a strong commitment to innovation [27][29]. - Kelun Biotech is recognized as a leader in the ADC field, with a well-established integrated R&D platform and significant partnerships, particularly with Merck [1][34]. Product Pipeline - The ADC pipeline includes SKB264, the first domestic TROP2 ADC, and A166, the first HER2 ADC for breast cancer, both expected to launch soon [1][35]. - The company also has a rich reserve of non-ADC products, with approvals anticipated in various therapeutic areas, including rheumatoid arthritis and asthma [1][6]. Market Position - The company maintains a leading position in the domestic infusion market, with innovative products like the "Keli Bag" enhancing cash flow [1][24]. - The antibiotic intermediate segment is also a key growth area, benefiting from market recovery and increased efficiency [1][6].